Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neutralizing monoclonal antibodies versus favipiravir in mild to moderate COVID-19 outpatients
TCTR20230912002Completed
- Sponsor
- Chulabhorn Royal Academy
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Trial of favipiravir in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Chulabhorn Royal Academy. Started Sep 2021; status: completed.
02
Drugs
favipiravir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on TCTR20230912002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20230912002.